Literature DB >> 26294727

Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Eleonora Fonte1, Andreas Agathangelidis2, Daniele Reverberi3, Stavroula Ntoufa4, Lydia Scarfò5, Pamela Ranghetti2, Giovanna Cutrona3, Alessandra Tedeschi6, Aliki Xochelli4, Federico Caligaris-Cappio5, Maurilio Ponzoni7, Chrysoula Belessi8, Zadie Davis9, Miguel A Piris10, David Oscier9, Paolo Ghia11, Kostas Stamatopoulos12, Marta Muzio2.   

Abstract

Recent studies on splenic marginal zone lymphoma identified distinct mutations in genes belonging to the B-cell receptor and Toll-like receptor signaling pathways, thus pointing to their potential implication in the biology of the disease. However, limited data is available regarding the exact role of TLRs. We aimed at characterizing the expression pattern of TLRs in splenic marginal zone lymphoma cells and their functional impact on the activation, proliferation and viability of malignant cells in vitro. Cells expressed significant levels of TLR1, TLR6, TLR7, TLR8, TLR9 and TLR10 mRNA; TLR2 and TLR4 showed a low, variable pattern of expression among patients whereas TLR3 and TLR5 mRNAs were undetectable; mRNA specific for TLR signaling molecules and adapters was also expressed. At the protein level, TLR1, TLR6, TLR7, TLR9 and TLR10 were detected. Stimulation of TLR1/2, TLR2/6 and TLR9 with their respective ligands triggered the activation of IRAK kinases, MAPK and NF-κB signaling pathways, and the induction of CD86 and CD25 activation molecules, although in a heterogeneous manner among different patient samples. TLR-induced activation and cell viability were also inhibited by a specific IRAK1/4 inhibitor, thus strongly supporting the specific role of TLR signaling in these processes. Furthermore, TLR2/6 and TLR9 stimulation also significantly increased cell proliferation. In conclusion, we demonstrate that splenic marginal zone lymphoma cells are equipped with functional TLR and signaling molecules and that the stimulation of TLR1/2, TLR2/6 and TLR9 may play a role in regulating disease pathobiology, likely promoting the expansion of the neoplastic clone. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26294727      PMCID: PMC4825289          DOI: 10.3324/haematol.2014.119933

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  37 in total

1.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Authors:  Eleni Arvaniti; Stavroula Ntoufa; Nikos Papakonstantinou; Tasoula Touloumenidou; Nikolaos Laoutaris; Achilles Anagnostopoulos; Klea Lamnissou; Federico Caligaris-Cappio; Kostas Stamatopoulos; Paolo Ghia; Marta Muzio; Chrysoula Belessi
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

Review 2.  Toll-like receptor and RIG-I-like receptor signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

3.  Toll-like receptor signaling pathways.

Authors:  Gregory M Barton; Ruslan Medzhitov
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

Review 4.  Splenic marginal zone lymphoma: disease features and management.

Authors:  Estella Matutes
Journal:  Expert Rev Hematol       Date:  2013-10-30       Impact factor: 2.929

5.  In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.

Authors:  Eleonora Fonte; Benedetta Apollonio; Lydia Scarfò; Pamela Ranghetti; Claudia Fazi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

6.  BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Authors:  Qingguo Yan; Yuanxue Huang; A James Watkins; Sylvia Kocialkowski; Naiyan Zeng; Rifat A Hamoudi; Peter G Isaacson; Laurence de Leval; Andrew Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 7.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

Review 8.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

Review 9.  Splenic marginal-zone lymphoma: ontogeny and genetics.

Authors:  Panagiotis Baliakas; Jonathan C Strefford; Vasilis Bikos; Marina Parry; Kostas Stamatopoulos; David Oscier
Journal:  Leuk Lymphoma       Date:  2014-08-19

10.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

View more
  9 in total

1.  The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.

Authors:  Vanessa Stache; Lydia Verlaat; Marcel Gätjen; Kristina Heinig; Jörg Westermann; Armin Rehm; Uta E Höpken
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

2.  IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.

Authors:  Federica Riva; Maurilio Ponzoni; Domenico Supino; Maria Teresa Sabrina Bertilaccio; Nadia Polentarutti; Matteo Massara; Fabio Pasqualini; Roberta Carriero; Anna Innocenzi; Achille Anselmo; Tania Veliz-Rodriguez; Giorgia Simonetti; Hans-Joachim Anders; Federico Caligaris-Cappio; Alberto Mantovani; Marta Muzio; Cecilia Garlanda
Journal:  Cancer Immunol Res       Date:  2019-04-24       Impact factor: 11.151

3.  Transcriptional Profiling of Non-Human Primate Lymphoid Organ Responses to Total-Body Irradiation.

Authors:  David L Caudell; Kristofer T Michalson; Rachel N Andrews; William W Snow; J Daniel Bourland; Ryne J DeBo; J Mark Cline; Gregory D Sempowski; Thomas C Register
Journal:  Radiat Res       Date:  2019-05-06       Impact factor: 2.841

4.  Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.

Authors:  Matteo Sbattella; Andrea Zanichelli; Paolo Ghia; Valter Gattei; Chiara Suffritti; Thomas Teatini; Marco Cicardi; Roberto Castelli
Journal:  Med Oncol       Date:  2018-08-02       Impact factor: 3.064

5.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 6.  'Trained immunity': consequences for lymphoid malignancies.

Authors:  Wendy B C Stevens; Mihai G Netea; Arnon P Kater; Walter J F M van der Velden
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

7.  Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas.

Authors:  Zhi-Hua Ye; Li Gao; Dong-Yue Wen; Yun He; Yu-Yan Pang; Gang Chen
Journal:  Onco Targets Ther       Date:  2017-03-21       Impact factor: 4.147

8.  Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.

Authors:  Aurélie Verney; Alexandra Traverse-Glehen; Evelyne Callet-Bauchu; Laurent Jallades; Jean-Pierre Magaud; Gilles Salles; Laurent Genestier; Lucile Baseggio
Journal:  Oncotarget       Date:  2018-05-04

Review 9.  IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.

Authors:  Joshua Bennett; Daniel T Starczynowski
Journal:  Curr Opin Hematol       Date:  2022-01-01       Impact factor: 3.284

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.